Clinical trial · no report yet · Phase 1
NCT03738228
Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer
- NCT03738228 ↗
- Completed
- National Cancer Institute (NCI)
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB2 Cervical Cancer AJCC v8; Stage II Cervical Cancer AJCC v8; Stage IIA Cervical Cancer AJCC v8; Stage IIA1 Cervical Cancer AJCC v8; Stage IIA2 Cervical Cancer AJCC v8; Stage IIB Cervical Cancer AJCC v8; Stage IIIB Cervical Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8
- Interventions
- Atezolizumab; Brachytherapy; Cisplatin; Radiation Therapy
- Arms
- Arm A (atezolizumab, standard cisplatin and radiation therapy) · Experimental
- Arm B (atezolizumab, standard cisplatin and radiation therapy) · Experimental
- Enrollment
- 40
- Primary outcomes
- Immune Response
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jan 7, 2019
- Primary completion
- May 1, 2022
- Results posted
- Yes
- Registry record
- NCT03738228 · updated Nov 12, 2025
Publications
linked from the registry- Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer. 2020 May;30(5):701-704. doi: 10.1136/ijgc-2019-001012. Epub 2019 Dec 22. PubMed 31871115